Kodiak Sciences Inc.
KOD
Ранг среди акций
#3086
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Цена акции
$93.69
Рыночная капитализация
$5.89B
Изменение (1 день)
2.56%
Изменение (1 год)
429.32%
Страна
US
Торговля Kodiak Sciences Inc. (KOD)
Категория
Healthcare
История дроблений акций Kodiak Sciences Inc. (KOD)
Акции Kodiak Sciences Inc. (символ: KOD) прошли через 1 дроблений.
Последнее дробление произошло Feb 23, 2022.
Одна акция KOD, купленная до Feb 23, 2022, сейчас соответствует 5 акциям KOD.
Последнее дробление произошло Feb 23, 2022.
Одна акция KOD, купленная до Feb 23, 2022, сейчас соответствует 5 акциям KOD.
Список дроблений акций
| Год | Дробление | Коэффициент | Суммарный коэффициент |
|---|---|---|---|
| 2022-02-23 | 5:1 | x5 | x5 |
Дробления акций аналогичных компаний или конкурентов
| Компания | Количество дроблений акций | Суммарный коэффициент | Страна |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
